Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
Kyle Hayes,Mary P Panaccio,Parul Houston,John Niewoehner,Mohammed Fahim,George J Wan,Bhavna Dhillon
DOI: https://doi.org/10.2147/OARRR.S329766
2021-10-16
Open Access Rheumatology: Research and Reviews
Abstract:Kyle Hayes, 1 Mary P Panaccio, 1 Parul Houston, 1 John Niewoehner, 1 Mohammed Fahim, 2 George J Wan, 1 Bhavna Dhillon 3 1 Mallinckrodt Pharmaceuticals, Hampton, NJ, USA; 2 KMK Consulting, Morristown, NJ, USA; 3 United Rheumatology, Hauppauge, NY, USA Correspondence: Kyle Hayes Mallinckrodt Pharmaceuticals, Hampton, NJ, USA Tel +1 314-393-3531 Email Purpose: Repository corticotropin injection (RCI; Acthar ® Gel) is a naturally sourced mixture of adrenocorticotropic hormone analogs and other pituitary peptides that exerts anti-inflammatory and immunomodulatory properties via melanocortin receptors. RCI is approved as a short-term adjunctive therapy for rheumatoid arthritis (RA) and is typically used in patients with refractory RA. The objective of this study was to describe real-world outcomes of RA patients treated with RCI by retrospective analysis of an electronic medical records (EMR) database. Patients and Methods: EMR data were obtained from the United Rheumatology-Normal Integrated Community Evidence (UR-NICE TM ) data repository for patients who used RCI for the treatment of RA. Demographics, comorbidities, disease history, medications, and laboratory evaluations 365 days prior to and 365 days after initiation of RCI were examined. Results: The patient cohort was predominantly White females with a mean age of 60 years and high RA activity prior to RCI therapy. Clinical measures of disease severity indicated that patients had high RA activity before starting RCI therapy. Clinical Disease Activity Index (CDAI) scores were significantly reduced 365 days post-initiation of RCI. Swollen and tender joint counts and patient-reported outcomes, including Routine Assessment of Patient Index Data 3 (RAPID3), Physician Global Assessment, and patient assessment of pain severity were also significantly lower. The number of patients taking conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs), biologic (b) DMARDs, nonsteroidal anti-inflammatory drugs (NSAIDS), and opioids decreased, as did the number of drugs tried within each class for csDMARDs, bDMARDs, NSAIDs, and glucocorticoids. Conclusions: These findings suggest that RCI significantly improves clinical outcomes of RA and decreases the need for concomitant medications for up to 1 year following initiation of therapy. The study provides valuable insights into the use of RCI and management of these difficult-to-treat RA patients during routine clinical practice. Keywords: Acthar Gel, DMARDs, real-world evidence, rheumatoid arthritis, repository corticotropin injection, RCI, United Rheumatology database Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints and bone remodeling. 1 RA poses a significant burden to the health care system. 2 The goal for the management of RA is to achieve disease remission with a treat-to-target approach. Timely treatment of flares significantly impacts disease progression and outcomes. 3 The American College of Rheumatology (ACR) recommends initiating treatment with synthetic disease-modifying antirheumatic drugs (DMARDs) and progressing to biologic DMARDs if disease activity remains high. Low-dose glucocorticoids can be considered as an adjunct therapy for patients with moderate to severe RA or for patients in whom DMARDs fail. According to the ACR, glucocorticoids should only be used at the lowest possible dose for the shortest possible duration. 4 Despite treatment with DMARDs and glucocorticoids, many patients with RA continue to experience significant symptoms or flares. 5 Repository corticotropin injection (RCI; Acthar ® Gel) is a naturally sourced mixture of porcine-derived adrenocorticotropic hormone analogs and other pituitary peptides. RCI is US Food and Drug Administration–approved for use as an adjunctive therapy for short-term administration in RA. Detailed prescribing and safety information can be found in the prescribing label. 6 Studies have demonstrated that RCI acts as an agonist at all 5 melanocortin receptors (MCRs) with a unique binding and activation profile compared to other MCR agonists. 7 MC2R is found on adrenocortico cells and acts to stimulate glucocorticoid release; however, RCI shows its lowest full agonist activity at this receptor in vitro 7 and results in lower endogenous cortisol release in vivo compared with other MC2R agonists. 8 These and other published data indicate that RCI has a unique mechanism of action, distinct from glucocorticoids, and therefore may have different adverse effects than glucocorticoids; this h -Abstract Truncated-